Neobe Therapeutics
Neobe Therapeutics is a pioneering biotech company focused on transforming cancer treatment through engineered live biotherapeutics. They develop programmable microbial trojan horses to disrupt the tumor microenvironment, enabling immunotherapy success in patients with immune excluded tumors. Backed by leading scientific partners and investors, Neobe aims to address the barriers created by the tumor microenvironment that prevent immune infiltration, thereby expanding the benefits of immunotherapies to more patients.
Industries
Nr. of Employees
small (1-50)
Neobe Therapeutics
Salisbury House, Station Road, Cambridge, England, CB1 2LA
Products
Engineered tumor‑colonizing live biotherapeutic candidates (pre‑clinical)
Programmable bacterial therapeutic candidates engineered to colonize solid tumours and locally remodel the tumour microenvironment to enable immune infiltration and improve response to immunotherapies. Two differentiated candidates are described as being in pre-clinical development.
Engineered tumor‑colonizing live biotherapeutic candidates (pre‑clinical)
Programmable bacterial therapeutic candidates engineered to colonize solid tumours and locally remodel the tumour microenvironment to enable immune infiltration and improve response to immunotherapies. Two differentiated candidates are described as being in pre-clinical development.
Services
Joint research programmes with academic synbio and immunology groups and industry/investor partners to advance engineered live therapeutic concepts.
Design and execution of in vitro, ex vivo and in vivo experiments to screen and characterise engineered bacterial therapeutic candidates.
Joint research programmes with academic synbio and immunology groups and industry/investor partners to advance engineered live therapeutic concepts.
Design and execution of in vitro, ex vivo and in vivo experiments to screen and characterise engineered bacterial therapeutic candidates.
Expertise Areas
- Synthetic biology
- Live biotherapeutics development
- Tumour microenvironment remodelling
- Pre-clinical testing and validation
Key Technologies
- Synthetic biology
- Engineered live biotherapeutics
- Tumour‑responsive biosensors
- Tumour microenvironment remodelling
News & Updates
Neobe Therapeutics raises over $2m for synthetic biology enabled tumour microenvironment remodelling
Neobe Therapeutics announced the successful closure of a $2.34M financing round supported by new investors Pioneer Group and 2048 Ventures, along with existing backers. The company is developing a platform to engineer safe microbial strains to disrupt the microenvironment of solid tumours, with two products in pre-clinical development targeting high unmet clinical needs in cancer.
An article discussing Neobe's approach to using bacteria to overcome tumor defenses, highlighting their innovative strategy in immuno-oncology.
Neobe Therapeutics raises over $2m for synthetic biology enabled tumour microenvironment remodelling
Neobe Therapeutics announced a $2.34M financing round to support their work in engineering microbial strains to improve immunotherapy responses in cancer patients.
Neobe Therapeutics raises over $2m for synthetic biology enabled tumour microenvironment remodelling
Neobe Therapeutics announced the successful closure of a $2.34M financing round supported by new investors Pioneer Group and 2048 Ventures, along with existing backers. The company is developing a platform to engineer safe microbial strains to disrupt the microenvironment of solid tumours, with two products in pre-clinical development targeting high unmet clinical needs in cancer.
An article discussing Neobe's approach to using bacteria to overcome tumor defenses, highlighting their innovative strategy in immuno-oncology.
Neobe Therapeutics raises over $2m for synthetic biology enabled tumour microenvironment remodelling
Neobe Therapeutics announced a $2.34M financing round to support their work in engineering microbial strains to improve immunotherapy responses in cancer patients.